Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ALG-037287
- Development stage
- Preclinical
- Lead developer
- Aligos Therapeutics
- Modality
- Small Molecules
- Administration
- Oral
01
Overview
ALG-037287 is an orally bioavailable, liver-targeted small molecule inhibitor of fatty acid synthase (FASN) designed for the treatment of metabolic dysfunction-associated steatohepatitis (MASH). Developed by Aligos Therapeutics, the compound selectively targets the beta-ketoacyl reductase (KR) domain of FASN to suppress de novo lipogenesis (DNL) in the liver. By optimizing tissue distribution to achieve high liver-to-plasma concentration ratios and minimizing exposure in the skin, ALG-037287 aims to preserve therapeutic efficacy in MASH while reducing the risk of alopecia and other dermatological side effects associated with systemic FASN inhibition.
02
Targets
FASN (Fatty acid synthase)
Beyond the preview
Go deeper on ALG-037287.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ALG-037287.